Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 å resolution

Structure

Volumn 3, Issue 4, 1995, Pages 365-379

  Ding, J ^a   Das, K ^b   Tantillo, C ^a   Zhang, W ^a   Clark, Jr, AD ^a   Jessen, S ^a   Lu, X ^a   Hsiou, Y ^a   Jacobo Molina, A ^a   Andries, K ^b   Pauwels, R ^c   Moereels, H ^b   Koymans, L ^b   Janssen, PAJ ^b   Smith, Jr, RH ^d   Koepke, M Kroeger ^d   Michejda, CJ ^d   Hughes, SH ^d   Arnold, E ^a  

^a RUTGERS UNIVERSITY   (United States)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c R Pauwels TIBOTEC Institute for Antiviral Research Drie Eikenstraat 661 B 2650 Edegem Belgium ^*  (Belgium)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

AIDS; drug resistance; mechanism of non nucleoside; polymerase structure; protein drug interactions

Indexed keywords

5 MERCURIDEOXYURIDINE TRIPHOSPHATE; 5-MERCURIDEOXYURIDINE TRIPHOSPHATE; ACETAMIDE DERIVATIVE; ACETOPHENONE DERIVATIVE; ANTIVIRUS AGENT; DEOXYURIDINE PHOSPHATE; HIV 1 REVERSE TRANSCRIPTASE; HIV 2 REVERSE TRANSCRIPTASE; HIV-2 REVERSE TRANSCRIPTASE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; LOVIRIDE; METHYLMERCURY DERIVATIVE; ORGANOMERCURY COMPOUND; R 95845; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TETRAKIS(ACETOXYMERCURI)METHANE;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; FOURIER ANALYSIS; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PROTEIN BINDING; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; X RAY CRYSTALLOGRAPHY;

ACETAMIDES; ACETOPHENONES; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; BINDING SITES; COMPARATIVE STUDY; CRYSTALLOGRAPHY, X-RAY; DEOXYURACIL NUCLEOTIDES; DRUG RESISTANCE, MICROBIAL; FOURIER ANALYSIS; HIV ANTIBODIES; HIV-1 REVERSE TRANSCRIPTASE; IMMUNOGLOBULINS, FAB; METHYLMERCURY COMPOUNDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; ORGANOMERCURY COMPOUNDS; PROTEIN BINDING; PROTEIN CONFORMATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0029644484     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-2126(01)00168-X     Document Type: Article

References (69)

1. HIV reverse transcriptase structure–function relationships
2. Human immunodeficiency virus reverse transcriptase
3. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase: implications for mechanisms of drug inhibition and resistance
4. Inhibitors of HIV reverse transcriptase as antiviral agents and drug resistance
5. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents
6. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives
7. Inhibition of HIV-1 replication by a non-nucleoside reverse transcriptase inhibitor
8. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity
9. Non-nucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication
10. 2′,5′-Bis-O-(tertbutyl-dimethylsilyl)-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide) pyrimidine (TSAO) nucleoside analogs: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase
11. Non-nucleoside inhibitors of HIV-1 reverse transcriptase
12. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase
13. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors
14. HIV and multidrug resistance
15. Crystal structure at 3.5 å resolution of HIV-1 reverse transcriptase complexed with an inhibitor
16. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 å resolution shows bent DNA
17. Structure of the binding site for non-nucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1
18. Review of HIV-1 reverse transcriptase three-dimensional structure: implications for drug design
19. Comparison of three different crystal forms shows HIV-1 reverse transcriptase displays an internal swivel motion
20. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1
21. 2.2 å resolution structure of the amino-terminal half of HIV-1 reverse transcriptase (fingers and palm subdomains)
22. Improved methods for building protein models in electron density maps and the location of errors in these models
23. Improved Fourier coefficients for maps using phases from partial structures with errors
24. The CCP4 suite programs for protein crystallography
25. Buried surface analysis of HIV-1 reverse transcriptase p66/p51 heterodimer and its interaction with dsDNA template/primer
26. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer
27. Aromatic–aromatic interaction: a mechanism of protein structure stabilization
28. π-π interactions: the geometry and energetics of phenylalanine–phenylalanine interactions in proteins
29. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to non-nucleoside inhibitors
30. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple non-nucleoside inhibitors
31. Drug resistance of human immunodeficiency virus type 1 reverse transcriptase: subunit specificity of mutations that confer resistance to non-nucleoside inhibitors
32. Sensitivity of (138Glu→Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors
33. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[451-jk] [14] benzodiazepinone-2(1H)-one and -thione derivatives
34. A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site
35. Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to non-nucleoside analog inhibitors
36. Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse non-nucleoside inhibitors
37. Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by non-nucleoside inhibitors
38. Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2
39. Analysis of non-nucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase
40. Variability among HIV and SIV strains of African origin
41. An African primate lentivirus (SIVsm) closely related to HIV-2
42. Genetic organization of a chimpanzee lentivirus related to HIV-1
43. Evolutionary origin of human and simian immunodeficiency viruses
44. Differential inhibitory effects of TIBO derivatives on different strains of simian immunodeficiency virus
45. Effect of a thiobenzimidazolone derivative of DNA strand transfer catalyzed by HIV-1 reverse transcriptase
46. Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase
47. Crystallographic analysis of an active HIV-1 ribonuclease H domain shows structural features that distinguish it from the inactive form
48. Mutating the ‘primer grip’ of p66 HIV-1 reverse transcriptase implicates tryptophan-229 in template-primer utilization
49. Structure of HIV-1 reverse transcriptase/DNA complex at 7 å resolution showing active site locations
50. Crystallization of HIV-1 reverse transcriptase in the presence and absence of nucleic acid substrates, inhibitors, and an antibody Fab fragment
51. Local scaling a method to reduce systematic errors in isomorphous replacement and anomalous scattering measurements
52. Extension of molecular replacement a new strategy based on Patterson correlation refinement
53. Halloween, masks and bones
54. The free R value: a novel statistical quantity for assessing the accuracy of crystal structures
55. Traitement statistique des erreurs dans la determination des structures cristallines
56. PROCHECK a program to check the stereochemical quality of protein structures
57. Development and analysis of human immunodeticiency virus type 1 resistant to HIV-1 specific pyridinone reverse transcriptase inhibitors
58. Prevention of the spread of HIV-1 infection with non-nucleoside reverse transcriptase inhibitors
59. HIV-1-specific reverse transcriptase inhibitors show differential activity against mutant strains containing different amino acid substitutions in the reverse transcriptase
60. Human immunodeficiency virus type 1 mutants resistant to non-nucleoside inhibitors of reverse transcriptase arise in tissue culture
61. Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication
62. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other non-nucleoside inhibitors
63. MOLSCRIPT a program to produce both detailed and schematic plots of protein structures
64. Nucleotide sequence of the AIDS virus, LAV
65. Molecular cloning and polymorphism of the human immune deficiency virus type 2
66. Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses
67. Complete nucleotide sequence of a simian immunodeficiency virus from African green monkeys: a novel type of intragroup divergence
68. Sequence of a novel simian immunodeficiency virus from a wild-caught African mandrill